The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 28 February 2026•Updated 28 February 2026•

1 min read

DBV Technologies Bolsters VITESSE Trial Results with Strong Comparative Data for Peanut Allergy Patch

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

Key Facts

1Results showed 83% of children treated with the VIASKIN Peanut Patch increased their eliciting dose compared to 48% in the placebo group.

3 months ago

Version History

Version 13 months ago

What changed: The story was updated with precise comparative data against the placebo group, highlighting the treatment's ability to prevent allergy worsening, and adding details about the presentation location and the company's dual listing status.

DBV Technologies presented detailed Phase 3 VITESSE trial data for its VIASKIN Peanut Patch during an oral presentation in Philadelphia, further strengthening its clinical profile. The findings showed that 83% of treated children increased their eliciting dose, significantly outperforming the 48% in the placebo group. Notably, 60% of treated subjects achieved a two-dose increase, compared to just 23% of those receiving the placebo. The patch also demonstrated a protective effect, with only 6.4% of treated subjects seeing a dose decrease versus 24% in the placebo group. As the largest food allergy immunotherapy trial to date, these results solidify the path toward regulatory submission for children aged 4 to 7. Listed on both Euronext Paris (DBV) and Nasdaq (DBVT), the company is now well-positioned for potential commercialization and significant future revenue growth.